Brucella abortus immune marking recombinant strain and application thereof in preparation of vaccine

Abstract

The invention discloses brucella abortus immune marking recombinant strain and the application thereof in preparation of vaccine. The recombinant strain is obtained by inactivating glycosyltransferase gene in the brucella abortus. The recombinant bacterial strain has weaker toxicity, can be taken as vaccine to immunize animals without inactivation, and can distinguish immune vaccinated animals from clinically diseased animals by means of a serological technology. By being immunized with the strain of the invention, a mouse generates antibody and standard bacterial strain which are different from the existing strain, so that the diseased animals can be distinguished from the immunized animals by the immunological test of animal sera. The invention is applicable to improving the brucella abortus vaccine, researching diagnosis identification agent, and developing the brucella abortus vaccine and the matched diagnosis identification agent, and has significant meaning for eradicating and cleaning the brucella abortus of the animals in the world.

Description

technical field [0001] The invention relates to a Brucella abortus immunomarker recombinant strain and its application in vaccine preparation. Background technique [0002] Brucellosis is a zoonotic infectious disease, second only to foot-and-mouth disease among large animal infectious diseases, and has important political and economic influences. The epidemic situation in countries around the world is very serious. For a long time, the global strategy for the prevention and control of brucellosis has been mainly quarantine-culling (in developed countries) or immunization (in developing countries). The former uses quarantine and culling of sick cattle, sheep, pigs and other animals as a measure, which costs a lot of money , Difficult to operate; the latter can prevent the spread of the disease in the animal population through immunization and auxiliary culling measures, but it is difficult to distinguish the immune animals from the clinically diseased animals, which makes th...

AI Technical Summary

Problems solved by technology

For a long time, the global strategy for the prevention and control of brucellosis has been mainly quarantine-culling (in developed countries) or immunization (in developing countries). The former uses quarantine and culling of sick cattle, sheep, pigs and other animals as a measure, which costs a lot of money , Difficult to operate; the latter can prevent the spread of the disease in the animal population through immunization and auxiliary culling measures, but it is difficult to distinguish the immune animals from the clinically diseased animals, which makes the diseased animals exist in the natural population for a long time, posing a serious threat Human and fauna health, hindering eradication and decontamination of animal brucellosis

[0003] According to the current international and domestic use, the rough vaccine strain RB51 and the vaccine strain S19 are both attenuated live vaccines, but S19 is highly virulent, and it is easy to cause abortion when inoculated into female animals. Serological methods cannot be used to distinguish infection from wild strains; The virulence of RB51 is relatively weak. Although serological differential diagnosis can be made, the immune efficacy of RB51 is controversial and has not been used in my country.

Images